A first-in-human, open-label phase 1b and a randomised, double-blind phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab
(Neither the FDA nor HHS responded to ProPublicas requests for more information.) But several regulatory shortcuts exist and, ultimately, Kennedy could simply declare the ingredients are legal
Both antibodies were well-tolerated with no newly identified safety concerns, and with the most frequently reported adverse events (AEs) being headache (which occurred in all groups), muscle spasms, mouth ulcerations, and upper respiratory tract infections
Here are some suggestions of outcomes to look at: If you are deficient in riboflavin, you will absorb a lot more of it
Results may vary
Despite these findings, the direct impact of GLP-1R signaling on T cell biology remains to be fully elucidated